Amalgamated Bank Has $372,000 Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Amalgamated Bank decreased its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 4.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,617 shares of the specialty pharmaceutical company’s stock after selling 418 shares during the period. Amalgamated Bank’s holdings in Collegium Pharmaceutical were worth $372,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Caxton Associates LP acquired a new position in shares of Collegium Pharmaceutical in the 1st quarter valued at about $1,730,000. Foundry Partners LLC acquired a new position in shares of Collegium Pharmaceutical in the 2nd quarter valued at about $492,000. O Shaughnessy Asset Management LLC increased its holdings in shares of Collegium Pharmaceutical by 159.3% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 45,735 shares of the specialty pharmaceutical company’s stock valued at $1,775,000 after purchasing an additional 28,100 shares during the period. Vanguard Group Inc. increased its holdings in shares of Collegium Pharmaceutical by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 2,330,728 shares of the specialty pharmaceutical company’s stock valued at $90,479,000 after purchasing an additional 17,942 shares during the period. Finally, Squarepoint Ops LLC increased its holdings in shares of Collegium Pharmaceutical by 194.5% in the 2nd quarter. Squarepoint Ops LLC now owns 110,338 shares of the specialty pharmaceutical company’s stock valued at $3,553,000 after purchasing an additional 72,874 shares during the period.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 19,248 shares of the company’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total transaction of $737,198.40. Following the completion of the sale, the executive vice president now owns 120,161 shares of the company’s stock, valued at $4,602,166.30. This represents a 13.81 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Thomas B. Smith sold 9,593 shares of the stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $36.62, for a total value of $351,295.66. Following the completion of the sale, the executive vice president now directly owns 53,816 shares of the company’s stock, valued at $1,970,741.92. This represents a 15.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Stock Down 2.3 %

Shares of Collegium Pharmaceutical stock opened at $29.58 on Monday. The stock has a market capitalization of $953.96 million, a P/E ratio of 12.75 and a beta of 0.95. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The stock has a 50 day moving average price of $36.36 and a two-hundred day moving average price of $35.01. Collegium Pharmaceutical, Inc. has a 12-month low of $24.61 and a 12-month high of $42.29.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Needham & Company LLC reiterated a “hold” rating on shares of Collegium Pharmaceutical in a report on Friday, August 9th. Truist Financial increased their price objective on Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Friday, August 9th. HC Wainwright increased their price objective on Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, September 5th. Piper Sandler restated a “neutral” rating and issued a $37.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, October 11th. Finally, StockNews.com downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.60.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.